HOME >> MEDICINE >> NEWS
Treatment of ductal carcinoma in situ varies widely in United States

A new study has found that treatment of ductal carcinoma in situ (DCIS), a group of abnormal cells confined to the breast ducts, varies widely in the United States. Treatment ranges from potential overtreatment with aggressive surgical therapy to possible undertreatment by not providing radiation therapy after breast-conserving surgery, according to the study, which is published in the March 17 issue of the Journal of the National Cancer Institute.

The incidence of DCIS has increased dramatically in the last few decades, largely because of increased rates of screening mammography. In some cases, DCIS can progress to invasive cancer, but little is known about the characteristics that determine whether or not DCIS will progress to cancer.

To examine current patterns of care of DCIS, Nancy Baxter, M.D., Ph.D., of the University of Minnesota, and colleagues examined data from the Surveillance, Epidemiology, and End Results program for 25,206 women diagnosed with DCIS from 1992 to 1999. They found that the number of cases of DCIS increased 73% during the study period. Overall, 97.5% of patients had some type of surgery. The proportion of patients who had a mastectomy declined from 43% to 28% during the study period.

Overall, 64% of women with DCIS had breast-conserving surgery. In 1992, 45% of the patients who had breast-conserving surgery received radiation therapy, compared with 54% in 1999. The use of axillary dissection overall--the removal of the lymph nodes in the armpit to test for possible spread of disease--declined from 34% in 1992 to 15% in 1999. Among women who had a mastectomy over the entire study period, 42% also had axillary dissection, even though this procedure was not routinely recommended during the study period. Both radiation therapy and axillary dissection were more common among women whose DCIS had more aggressive characteristics.

"According to our study, many patients apparently underwent aggressive surgi
'"/>

Contact: Katherine Arnold
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
16-Mar-2004


Page: 1 2

Related medicine news :

1. Treatment of cardiac lesions without anaesthesic
2. Treatment guidelines for kids with bipolar disorder published
3. University of Washington joins new Autism Treatment Network to provide better medical services
4. Treatment for brain tumor does not always follow recommendations
5. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
6. Treatment options expand for patients with neuropathic pain
7. Treatment interruption shows no benefit in drug-resistant HIV infection
8. Peanut Allergy: Major Advances in Treatment and Education
9. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
10. Treatment helped reduce dose of inhaled corticosteroids while maintaining asthma control
11. Treatment for behavioral disorders in children with autism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Treatment ductal carcinoma situ varies widely United States

(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, a ... injured by defective medical devices, is offering remarks on the ... the Estate of Fred E. Taylor v. Intuitive Surgical, 09-2-03136-5, ... May 21, 2013, Bloomberg report noted that the ... a “car dealership” in how it deployed its strategy to ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Global Proving Ground (GPG), a fast rising ... retailer of health and fitness supplements, are partnering up ... Island. “We cast the show by having millions ... our unique social networking platform,” states show’s creator James ... an island in the Pacific Ocean, where they must ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
(Date:5/21/2013)... Fla. , May 21, 2013  BioRestorative Therapies, ... life sciences company focused on developing stem cell based ... Mark Weinreb , its President and CEO, will ... The conference will be held on Thursday, May ... 109 E 42nd Street in New York City.  Mr. ...
(Date:5/21/2013)... May 21, 2013 Ceregene, Inc. today ... of its double-blind, randomized, controlled Phase 2b clinical ... therapy product designed to deliver the neurotrophic factor ... a more robust response to CERE-120 in Parkinson,s ... relative to those diagnosed 10 years or more ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
Cached News: